Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Metastatic Hormone Refractory Prostate Cancer Clinical Trial

Official title:
A Phase 1b Clinical Trial of Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Status Active, not recruiting

Clinical Trial Summary

The goal of this study is to determine the recommended phase 2 dose of the multi-drug combination of abiraterone, cabozantinib, and nivolumab in conjunction with ongoing androgen deprivation therapy in previously untreated metastatic hormone-sensitive prostate cancer patients. The investigators hypothesize that the combination of cabozantinib and abiraterone acetate/prednisone in conjunction with nivolumab will have an acceptable safety profile and will be feasible to administer in patients with hormone-sensitive metastatic prostate cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Metastatic Hormone Refractory Prostate Cancer
Prostatic Neoplasms

Clinical Trial Details

NCT number	NCT04477512
Study type	Interventional
Source	Washington University School of Medicine
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	February 19, 2021
Completion date	March 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00766324` - PHA-739358 for Treatment of Hormone Refractory Prostate Cancer	Phase 2
Completed	`NCT00411528` - Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer	Phase 2
Completed	`NCT00636090` - Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001	N/A